cerca CERCA
Venerdì 15 Gennaio 2021
Aggiornato: 15:50

SALUTE E BENESSERE

Covid-19 vaccination campaign safety : France rolls out the "Medication Shield" of Synapse Medicine

BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM). This technology comes out as a valuable time-saver, supporting the management of adverse drug reaction (ADR) reports by makin...

Sicurezza della campagna vaccinale Covid-19: la Francia lancia "Medication Shield" di Synapse Medicine

BORDEAUX, Francia, 15 gennaio 2021 /PRNewswire/ -- Synapse Medicine, fondata da personale medico del settore pubblico, lancia la tecnologia Medication Shield per garantire la campagna vaccinale COVID-19 in Francia, in collaborazione con i centri regionali di farmacovigilanza (CRPV) e l'Agenzia nazionale francese per la sicurezza dei medicinali e dei prodotti per la salute (ANSM). Questa tecnologia garantisce un prezioso risparmio di tempo, facilitando la gestione delle segnalazioni di reazioni av...

NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis

MILAN, Italy and HONG KONG, Jan. 14, 2021 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in the People's Republic...

Cytiva delivers modular biologics factory to Lonza

AMERSHAM, United Kingdom, Jan. 14, 2021 /PRNewswire/ -- Cytiva, a global life sciences leader, has successfully completed another KUBio installation, this time to global healthcare solutions provider Lonza, in Guangzhou Biopark, China.  The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.

Seegene's COVID-19 test with saliva sample collection feature now available in Europe

SEOUL, South Korea, Jan. 14, 2021 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, and that the products with the feature are now available in Europe. The new addition of the saliva sample collection feature is set to offload the burden of collecting a large volume of specimen sample...

Caliber Ophthalmics Opens New State-of-the-Art Ophthalmology Center of Excellence

SINKING SPRING, Pa., Jan. 13, 2021 /PRNewswire/ -- Caliber Ophthalmics, a Surgical Specialties Corporation company, is pleased to announce the opening of a state of the art ophthalmology design and manufacturing Center of Excellence in Sinking Spring, PA. The newly renovated 23,000 square foot facility has a clean room for precision manufacturing of medical devices, an engineering design center, and advanced blade manufacturing capabilities. The site combines the two exceptional teams with decade...

SKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients

LONDON, Jan. 13, 2021 /PRNewswire/ -- LumiraDx, the next generation point-of-care diagnostic company, announced today that the Scandinavian evaluation of laboratory equipment for point of care testing (SKUP) had published a positive evaluation of the LumiraDx SARS-CoV-2 Antigen Test. In a mixed population of symptomatic and asymptomatic subjects tested in point of care settings, the test achieved 87-90% agreement with RT-PCR which increased to 92-95% in patients with viral load corresponding to C...

Il Partner di RedHill, Cosmo Pharmaceuticals, ha completato con successo lo studio di Fase II di Rifamycin SV-MMX 600 mg nell'IBS-D

TEL AVIV, Israele e RALEIGH, N.C., 13 gennaio 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" o "la Società"), un'azienda biofarmaceutica specializzata, ha riferito oggi che il suo partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), ha annunciato di aver completato con successo lo studio clinico Proof-of-Concept (POC) di Fase II su Rifamycin SV-MMX 600 mg in pazienti affetti da sindrome dell'intestino irritabile con diarrea predominante (IBS-D). 

LI-COR Biosciences fornisce supporto diretto ai clienti in Italia

LINCOLN, Nebraska e BAD HOMBURG, Germania, 12 gennaio 2021 /PRNewswire/ -- LI-COR Biosciences è lieta di annunciare che sta attualmente fornendo vendite, supporto e servizi direttamente ai clienti biotecnologici in Italia. I clienti italiani di LI-COR per la linea di prodotti ambientali continuano a essere supportati da Ecosearch Srl.

ora in
Prima pagina
Tag più usati
in questa pagina

immediapress

press release

comunicati

aziende informano

roma

coronavirus

video

ripresa

diretta

articoli
in Evidenza